Arthrobic

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arthrobic

What is Arthrobic? (Foundational Identity)

Arthrobic is a medicinal product whose active component is Meloxicam, officially categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification places it within the group of medicines used to manage systemic symptoms stemming from inflammatory processes throughout the body. The fundamental properties of this compound are clinically recognized for their efficacy in controlling key inflammatory markers.

Property Description
Active Ingredient Meloxicam (INN)
Forms Tablet, Solution for Injection, Oral Suspension, Suppository
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose Anti-inflammatory, Analgesic (Pain Relief), Antipyretic (Fever Reduction)
Origin Synthetic Oxicam Derivative

What is Arthrobic and How is it Classified? (Identity and Classification)

Arthrobic is a prescription-only medicine (Rx) containing the active substance Meloxicam, which belongs to the widely used pharmacological class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). As an oxicam derivative, Meloxicam is a synthetic compound, manufactured through chemical processes, and is specifically known as a preferential selective COX-2 inhibitor. This preferential action differentiates it from older, less selective NSAIDs, a property supported by pharmacological studies internationally.

Composition, Origin, and Available Forms

The therapeutic efficacy of Arthrobic is derived from its single active component, Meloxicam, which ensures consistency as a single-ingredient product. The medicine is prepared in various high-level preparations, including the standard tablet (for oral intake), a solution for injection (for parenteral administration), an oral suspension, and a suppository (for rectal use). This comprehensive offering of dosage forms means that Arthrobic provides flexibility for administration, whether an immediate route is required or a long-term route is preferred.

General Purpose: Anti-Inflammatory and Analgesic Action

The general purpose of Arthrobic is to deliver robust anti-inflammatory and analgesic relief by addressing the underlying cause of inflammation and pain. Meloxicam achieves this systemic effect by inhibiting the production of specific chemical messengers, primarily prostaglandins, which are responsible for initiating swelling, transmitting pain signals, and causing fever. Consequently, the medicine's role is to mitigate the discomfort and physical effects associated with these three main symptoms across the body.

Regulatory References

  1. Meloxicam (oral route) - MedlinePlus

What side effects are possible with Arthrobic?

Possible Side Effects and Safety Information

The safety profile of Arthrobic (Meloxicam) is formally defined by its adverse reaction classifications and specific regulatory warnings, primarily focusing on gastrointestinal and cardiovascular risks.


Official Adverse Reaction Categories

Adverse effects are categorized by frequency and grouped into System-Organ Classes (SOCs), with Gastrointestinal Disorders being the most frequently reported. These range from common symptoms such as dyspepsia, nausea, abdominal pain, constipation, and diarrhoea (often classified as Very Common or Uncommon in regulatory documents) to rare but serious events.


Serious Adverse Reactions

Regulatory labeling highlights the potential for Serious Cardiovascular Thrombotic Events, including Myocardial Infarction and Stroke, which may occur early in treatment and can increase with duration of use. The medicine also carries a significant risk for Serious Gastrointestinal Adverse Events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Other serious events include Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), with the highest risk for these severe skin reactions being early in treatment.


Population-Specific Safety Notes

The medicine is subject to specific safety limitations for certain populations. Older adults are at a heightened risk for serious GI adverse events. Use is generally contraindicated after 30 weeks of pregnancy due to risks to the fetus. Furthermore, official labeling advises against use in the setting of coronary artery bypass graft (CABG) surgery and in cases of severe, non-dialyzed renal or hepatic impairment.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Arthrobic


Overdose Scope

Classification/Finding Regulatory Statement/Manifestation
Documented Manifestations Nausea, Vomiting, Epigastric pain, Drowsiness, and Lethargy are documented as common presentations.
Physiological Systems Affected Severe overexposure is officially documented to affect the Gastrointestinal, Renal, Cardiovascular, and Central Nervous Systems (CNS).
Dose-Related Factors Exposure significantly above the recommended therapeutic dose may lead to severe outcomes.
Population-Specific Note Elderly patients and those with a prior history of gastrointestinal issues are identified as being at greater risk for serious GI events.
Emergency-Response Management involves symptomatic and supportive care. Procedures include administering activated charcoal and the use of Cholestyramine to accelerate elimination.
Urgent Medical Help Required Patients must seek medical attention immediately upon suspicion of overexposure.

Overdose Classifications (High-Level)

Classification Type Official Regulatory Description
Severity Classification Overdose is classified as having the potential for serious and life-threatening outcomes, including Acute renal failure, Coma, Convulsions, and Cardiac arrest.
Overdose-Context Constraint No specific antidote is known for Meloxicam overdose.

Resulting Overdose Structure

Official regulatory documents define the Meloxicam overdose profile by documenting common initial manifestations alongside the potential for severe systemic toxicity affecting renal, cardiovascular, and neurological systems. This potential for life-threatening outcomes mandates that patients seek medical attention immediately for suspected overexposure. The required management is defined as symptomatic and supportive, with specific documented procedural measures listed due to the confirmed absence of a specific antidote.

Therapeutic Uses of Arthrobic

What Arthrobic Treats: Main Uses and Benefits

The medicine may be part of symptomatic management for chronic and acute conditions characterized by periods of heightened symptoms related to inflammation and pain. The medicine is commonly used to help with symptoms related to inflammatory or irritative states, such as tenderness, swelling, and stiffness, which contributes to easing the overall symptom load on the patient.


Key Therapeutic Contexts

This medicine is primarily relevant in clinical settings marked by the discomfort of long-term inflammatory and degenerative conditions, including Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). It may also be applied when short-term symptomatic assistance is appropriate, such as for the management of moderate-to-severe pain with an inflammatory component. In specialized contexts, the medicine is also used for the symptomatic management of Juvenile Idiopathic Arthritis (JIA) in children.

It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive, assisting patients with maintaining functional stability when symptoms become more noticeable.


Quick Fact: May assist with Functional Stiffness


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Arthrobic? (Official Eligibility Rules)

Official regulatory documents define specific population eligibility rules for Arthrobic (Meloxicam), an NSAID, based on age, physiological status, and underlying conditions. Use is established in adult patients and pediatric patients ge 2 years of age for Juvenile Rheumatoid Arthritis.

Absolute Contraindications

Arthrobic is contraindicated in several specific populations and conditions as stated in regulatory labeling:

  • Patients with a known hypersensitivity to meloxicam or who have experienced asthma or allergic reactions after taking aspirin or other NSAIDs.
  • Individuals in the third trimester of pregnancy (beginning at 30 weeks gestation) and patients receiving treatment for peri-operative pain in the setting of CABG surgery.
  • Patients with active gastrointestinal bleeding, ulceration, or severe renal failure (non-dialyzed).

Restricted and Conditional Use

Use requires caution and is restricted in several groups, including geriatric patients (ge 65 years) due to increased risks. Patients with advanced renal disease or those on hemodialysis require a limited dosage. For pregnant women between 20 and 30 weeks gestation, use is conditional and limited to the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

This section describes the officially documented interaction patterns for Arthrobic (Meloxicam) as stated in regulatory prescribing information.

Contraindicated and Avoided Combinations

The use of Arthrobic for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery is formally contraindicated. Co-administration of the oral suspension formulation is contraindicated with Sodium Polystyrene Sulfonate due to the documented risk of intestinal necrosis. Regulatory documents also advise that co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including other COX-2 inhibitors and Ketorolac, should be avoided due to the additive risk of serious gastrointestinal adverse events.


Interactions Affecting Exposure and Toxicity

Meloxicam may increase the plasma concentrations of Methotrexate and Lithium, primarily through reduced renal clearance. This interaction carries an increased risk of toxicity for both medicines. The drug is metabolized predominantly by the hepatic enzyme CYP2C9. Individuals classified as CYP2C9 Poor Metabolizers are documented to have higher systemic Meloxicam exposure and an increased risk of adverse reactions.


Pharmacodynamic Risk Amplification

Co-administration with Anticoagulants (such as Warfarin), Antiplatelet Agents (including low-dose Aspirin), SSRIs/SNRIs, and Corticosteroids officially increases the documented risk of bleeding complications and gastrointestinal ulceration. Additionally, the drug may diminish the antihypertensive or natriuretic effect of Diuretics, ACE Inhibitors, and ARBs, while simultaneously increasing the risk of renal function deterioration. This renal risk is noted to be greater in the elderly and in patients with pre-existing renal impairment.

Mechanism of Action

The physiological action of Arthrobic (Meloxicam) is defined by its ability to influence the arachidonic acid cascade at the molecular level.

Preferential Inhibition of the Cyclooxygenase-2 ( COX-2) Enzyme System

The primary mechanism involves the preferential non-covalent inhibition of the Cyclooxygenase-2 ( COX-2) enzyme. This action targets a key molecular step in the arachidonic acid cascade, leading to a suppression in the synthesis of prostanoids, primarily prostaglandins ( PGE2), without fully suppressing the activity of the constitutive COX-1 enzyme. This modulation of the enzyme system acts by limiting the production of eicosanoid mediators that govern local biological responses.


Systemic Influence on Mediator-Driven Responses

The resulting suppression of prostaglandin synthesis affects various systemic responses. Reduced prostaglandin levels affect the chemical sensitization of peripheral sensory nerve endings and reset the elevated thermoregulatory set point in the hypothalamus. These simultaneous peripheral and central effects influence the nociception-temperature axis, generating predictable physiological alterations.

Dosage and Administration Information

General Principles of Administration

Arthrobic (Meloxicam) is officially approved for administration via multiple routes, including oral forms (tablets, capsules, or suspension), intravenous (IV) injection, and the rectal route via suppositories. The standard use pattern dictates that all approved adult regimens are taken once daily as a single dose.


Official Dosing and Scheduling

For oral administration in adults being managed for Osteoarthritis or Rheumatoid Arthritis, dosing typically begins at 7.5 mg once daily and may be increased to a maximum daily maintenance dose of 15 mg. For the injectable form used for pain management, the standard IV dose is 30 mg once daily. The overarching principle is to use the lowest effective dose for the shortest duration consistent with the overall treatment strategy.


Administration Requirements and Adjustments

Instructions regarding food intake vary by region: while some official labels permit taking the medicine without regard to meals, others instruct the medicine to be taken during a meal with water. For IV administration, the solution must be delivered as an intravenous bolus over 15 seconds, and patients must be well hydrated prior to injection. The maximum recommended daily dose must not be exceeded under any circumstance. Dose adjustments are stipulated for certain populations, such as a maximum oral dose of 7.5 mg per day for patients on hemodialysis. If a dose is missed, the patient should proceed with the next scheduled dose; a double dose should not be taken to compensate. The non-interchangeability of specific oral formulations is also noted.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Arthrobic

Evidence for Use in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

The main body of research for Arthrobic was conducted using Randomized Controlled Trials (RCTs), which form the basis of clinical evaluation. These trials were used to explore the effects in adult populations with symptomatic Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Studies were designed using both inactive comparators (placebo) and active comparators. Research examined outcomes related to physical discomfort (such as pain intensity) and outcomes reflecting daily functioning using standardized assessment tools.

Studies report patterns related to changes measured in patient-reported outcomes over short-term periods, typically lasting 4 to 12 weeks. However, follow-up durations were limited in many core RCTs, meaning long-term outcomes are not fully established based solely on this data. Information regarding continued symptomatic patterns is often derived from observational settings.

Evidence for Acute Pain and Ankylosing Spondylitis (AS)

Very short-term RCTs were used to study Arthrobic for acute pain in research exploring short-term symptom changes, such as in post-operative settings. For Ankylosing Spondylitis (AS), the research relies on evidence extrapolated from related inflammatory arthritides and long-term observational settings, as dedicated, large-scale RCTs are less common in regulatory summaries.

Evidence in Special Populations and Areas of Uncertainty

Research has explored the use of Arthrobic for Juvenile Idiopathic Arthritis (JIA) in pediatric patients using active-controlled trials over short durations (about 12 weeks). Data for certain groups remain insufficient, and research does not determine whether an individual will respond similarly to the reported group patterns. The studies do not examine any impact on underlying disease progression, and this remains a consistent research gap for this therapeutic class.

Frequently Asked Questions (FAQ)

Common questions about Arthrobic (FAQ)

Q: Can Arthrobic be taken on an empty stomach?

A: Official administration instructions for Arthrobic can vary. Some regulatory labels state the medicine can be taken without regard to meals, meaning food intake is not a factor. Other official sources, however, suggest taking the medicine during a meal with water. These differences highlight the importance of understanding the specific administration directions provided by the prescribing information.

Q: Can I take Arthrobic if I have a history of stomach problems?

A: Regulatory warnings indicate that patients with a prior history of peptic ulcer disease or gastrointestinal (GI) bleeding are at a greater risk for serious GI events like bleeding or perforation. This documented risk is noted in official information regarding patient eligibility and cautions for use.

Q: Does Arthrobic interact with common over-the-counter pain relievers like ibuprofen?

A: Official product information advises that co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common over-the-counter pain relievers like ibuprofen, should be avoided. This is because combining these medicines can lead to an increased, additive risk of serious gastrointestinal side effects.

Q: Does Arthrobic have any known interactions with herbal supplements?

A: Regulatory documentation acknowledges that interactions may occur with certain supplements. For example, some sources specifically cite ginkgo biloba as potentially increasing the risk of bleeding. Regulatory documents indicate that the potential for interaction is a factor when taking certain non-prescription items.

Q: Can Arthrobic affect my ability to drive or operate machinery?

A: Official regulatory documents note that the medicine may cause effects such as dizziness, drowsiness, or blurred vision in some individuals. Due to these potential effects, a person's ability to drive or operate complex machinery may be affected.

Q: Can Arthrobic cause issues with my kidneys?

A: Regulatory guidance states that Arthrobic is associated with a risk of renal function deterioration, which refers to a decline in kidney function. This may also increase the risk of kidney injury, particularly when used with certain other medicines or in patients who already have kidney impairment.

Q: Does Arthrobic have any known interactions with common high blood pressure medicines?

A: Official documentation states that Arthrobic may reduce the effect of certain high blood pressure medicines, including Diuretics, ACE Inhibitors, and ARBs. This combination may also simultaneously increase the risk of renal function deterioration (kidney issues).

Q: What is the storage temperature requirement for Arthrobic?

A: Official storage instructions state the medicine should be kept at Controlled Room Temperature, which is generally defined as 20 C to 25 C (or 68 F to 77 F). It is also required to be kept in a tight container and a dry place.

Q: Can I take other vitamins or supplements while on Arthrobic?

A: Regulatory information advises on potential interactions with certain herbal and potassium supplements. Regulatory documents indicate that the potential for interaction is a factor when taking certain non-prescription items.

Q: Is it common to feel tired or drowsy after taking Arthrobic?

A: Official adverse reaction lists do not typically include severe drowsiness as a very common effect, though dizziness is frequently reported. Drowsiness has been described in some post-marketing surveillance reports or when higher than recommended doses are used.

Q: How long can a person typically take Arthrobic?

A: Regulatory guidance emphasizes that the medicine should be used for the shortest duration consistent with the patient's treatment strategy. This is due to the documented risk of serious cardiovascular and gastrointestinal adverse events, which officially increase with the duration of use.

Q: Is Arthrobic habit-forming or addictive?

A: Arthrobic (Meloxicam) is formally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). According to U.S. federal classification, this medicine is not listed as a controlled substance, indicating it does not carry the risk of addiction or abuse associated with scheduled substances.

Q: Is Arthrobic a treatment or a medicine that helps manage symptoms?

A: Official research summaries indicate that the medicine addresses the signs and symptoms of inflammatory conditions, such as pain and swelling, by reducing inflammation. Studies and regulatory evidence do not currently examine any impact on the underlying progression of the disease itself.

Q: Is 'drug interaction' the same as 'drug-food interaction'?

A: Official drug documentation describes drug interactions (the effects when the medicine is combined with other medicines) and separately addresses the administration with or without food. This distinction suggests that these two areas—medicine-to-medicine effects and medicine-to-food effects—are described as separate areas of concern in regulatory labeling.

Q: What is the difference between an allergy to Arthrobic and a side effect?

A: Regulatory documents list hypersensitivity (an allergy) as an absolute contraindication, meaning the medicine must not be used if you have this condition. Side effects, on the other hand, are listed as known possible occurrences, ranging from common to serious events, in patients who are otherwise eligible to use the medicine.

Q: Is it possible to be allergic to the dye or coloring in the tablet?

A: Official regulatory documents list hypersensitivity to the active ingredient (meloxicam) or to any inactive ingredient as a contraindication. This indicates that an allergic response to any component, including the dye or coloring used in the formulation, is a documented safety concern.

Q: What should I do if I notice swelling in my hands or feet while on Arthrobic?

A: Official regulatory warnings mention that fluid retention and edema (swelling of the hands, ankles, or feet) are possible side effects that have been reported with the use of this medicine. The occurrence of this effect is noted as a possibility in official documentation.

Q: Is it normal to feel nauseous when starting Arthrobic?

A: Nausea is listed as one of the commonly reported gastrointestinal adverse effects in official documents. These types of common gastrointestinal effects are frequently observed during the initiation of treatment.

Q: Can Arthrobic affect my mood or sleep?

A: Official adverse reaction lists include effects on the nervous system, such as headache and dizziness. Some post-marketing surveillance reports have also included descriptions of mood changes and insomnia (trouble sleeping) as possible, though less common, effects.

Q: Does the medicine need to be taken consistently to work?

A: The medicine is typically prescribed to be taken once daily as a single dose for chronic conditions to help maintain steady levels in the body. Official instructions emphasize consistent, daily dosing and caution against exceeding the maximum recommended daily amount.

How should Arthrobic be stored and disposed of?

How to Store and Dispose of Arthrobic?

Arthrobic (meloxicam) must be stored and handled according to official regulatory labeling to ensure its stability and patient safety.

Official Storage Requirements

Requirement Category Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep in a tight container and a dry place to protect from moisture.
Safety Must be stored out of the reach of children.

Disposal Instructions

To discard unused or expired Arthrobic, do not dispose of it in household trash or wastewater (e.g., flush down the toilet). The medicine must be disposed of according to local regulations, often by returning it to a pharmacy or a designated collection point for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arthrobic found in:

A-Z Index: